A meta-analysis including two randomized controlled trials stated that using glucose gel as a treatment for neonatal hypoglycemia (NH) probably increases the correction of hypoglycemic events, decreases family separation, and increases exclusive breastfeeding rates [1]. Our group previously reported the glucose inconsistency within the tube of Glutose 15 (Paddock Laboratories, Minneapolis, MN), an oral glucose gel that is designed to treat hypoglycemia in adult diabetics but is also being used widely in the US to treat NH [2]. Thereafter, our hospital switched to the use of a new gel manufactured specifically for neonates, and packaged in pre-filled syringes, Sweet Cheeks (Dandle Lion Medical, Danbury, CT). Subsequently, our team reported inconsistency of glucose concentration within the syringe of Sweet Cheeks [3]. However, since the Sweet Cheeks syringe contains only about 1 to 2 doses, in contrast to approximately 11 doses in the tube of Glutose 15, the clinical significance of these findings is unknown. There are no studies comparing these two brands of glucose gel now commonly used in the US. The purpose of this study is to close this gap by comparing functional outcomes in newborns who were treated for NH using Glutose 15 to those given Sweet Cheeks.

This is an IRB-approved, single-center, retrospective cohort study comparing otherwise healthy newborns over 35 weeks of gestation in the mother-baby unit who were treated for NH with Glutose 15 (July 1, 2020–February 11, 2021) with infants treated for NH with Sweet Cheeks (February 12, 2021–January 8, 2022). All infants who were immediately admitted to the NICU after birth were excluded. Except for the brand of glucose gel they received, all newborns who experienced NH received the same care including skin-to-skin contact with the mother, frequent blood glucose monitoring, and early feeding (Supplementary Fig. 1). When glucose gel was indicated, nurses used gauze to dry the newborn’s mouth and then massaged 0.5 mL/kg of the gel into the buccal mucosa. Maternal and infant characteristics and outcomes were compared between the two cohorts. Analyses were performed utilizing IBM SPSS Version 29.

一项包括两项随机对照试验的荟萃分析表明，使用葡萄糖凝胶作为新生儿低血糖 (NH) 的治疗方法可能会增加低血糖事件的纠正，减少家庭分离，并提高纯母乳喂养率 [1]。我们小组之前曾报告过 Glutose 15（明尼苏达州明尼阿波利斯市 Paddock Laboratories）管内葡萄糖不一致的情况，Glutose 15 是一种口服葡萄糖凝胶，旨在治疗成人糖尿病患者的低血糖，但在美国也广泛用于治疗 NH [2] 。此后，我们医院转而使用专门为新生儿制造的新型凝胶，并包装在预填充注射器中，Sweet Cheeks（Dandle Lion Medical，丹伯里，康涅狄格州）。随后，我们的团队报告了 Sweet Cheeks 注射器内葡萄糖浓度不一致的情况 [3]。然而，由于 Sweet Cheeks 注射器仅含有约 1 至 2 剂剂量，而 Glutose 15 管中含有约 11 剂剂量，因此这些发现的临床意义尚不清楚。没有研究比较美国目前常用的这两个品牌的葡萄糖凝胶。本研究的目的是通过比较使用 Glutose 15 进行 NH 治疗的新生儿与接受 Sweet Cheeks 治疗的新生儿的功能结果来缩小这一差距。

这是一项经 IRB 批准的单中心回顾性队列研究，对母婴病房中妊娠超过 35 周、接受谷糖 15 NH 治疗（2020 年 7 月 1 日至 2021 年 2 月 11 日）的其他方面健康的新生儿与婴儿进行比较接受 Sweet Cheeks NH 治疗（2021 年 2 月 12 日至 2022 年 1 月 8 日）。所有出生后立即入住新生儿重症监护室的婴儿均被排除。除了所接受的葡萄糖凝胶品牌不同，所有经历过 NH 的新生儿都接受了相同的护理，包括与母亲的皮肤接触、频繁的血糖监测和早期喂养（补充图 1）。当需要使用葡萄糖凝胶时，护士用纱布擦干新生儿的口腔，然后将 0.5 mL/kg 的凝胶按摩至颊粘膜。比较了两个队列之间的母亲和婴儿的特征和结果。使用 IBM SPSS 版本 29 进行分析。